Diabetic Macular Edema

Primary Investigator: Elias Reichel, MD

Title: A Phase 4 Safety Study of IOP Signals in Patients Treated with ILUVIENĀ® (Fluocinolone Acetonide Intravitreal Implant) 0.19 mg

Inclusion Criteria: Patients who are eligible for treatment with ILUVIEN based on the prescribing information (treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure); If treatment for elevated IOP is necessary, laser trabeculoplasty must be used prior to use of any interventional, incisional IOP-lowering surgery, unless otherwise contraindicated.

Study Length and Visits: 16 visits, 3 years

Payment: None

Contact: Carly Satsuma, 617-636-5489, Mildred Commodore, 617-636-1051